✦ LIBER ✦

Daily induction treatment with alfa2b interferon in naive chronic hepatitis c patients results in a higher early response, a controlled multicenter randomized trial

✍ Scribed by Van Vlierberghe, Hans; Leroux-Roels, Geert; Bourgeois, Nadine; Nevens, Frederic; Colle, Isabelle; Henrion, Jean; Delwaide, Jean; Horsmans, Yves; Brenard, Reginald; Michielsen, Peter; Robaeys, Geert; Bruckers, Liesbeth

Book ID: 122391394
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 321 KB
Volume: 118
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(00)81890-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Response to higher doses of interferon a

Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial

✍ K L Lindsay; G L Davis; E R Schiff; H C Bodenheimer; L A Balart; J L Dienstag; R 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

JANICE ALBRECHT, 12 AND THE HEPATITIS INTERVENTIONAL THERAPY GROUP\* with continued therapy at that dose; however, a propor-To evaluate response rates to 3, 5, or 10 million units tion of patients who do not respond to 12 weeks of treat-(MU) of interferon alfa-2b, given thrice weekly, and to ment wi

Response to higher doses of interferon a

Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter tria

✍ KL Lindsay; GL Davis; ER Schiff; HC Bodenheimer; LA Balart; JL Dienstag; RP Perr 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

Treatment of Chronic Hepatitis due to He

Treatment of Chronic Hepatitis due to Hepatitis C Virus (CH-C) in India: A Randomized Controlled Trial Comparing Daily Interferon-alfa-2b and Ribavirin with Daily Interferon-alfa-2b and Glycyrrhizin—A Multicenter Study

✍ Subrat K Acharya; V Sreenivas; Siddharth Datta Gupta; Shakti Kumar; Yogesh K Cha 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 186 KB

Randomized controlled trial of pegylated

Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6

✍ Khoa D. Lam; Huy N. Trinh; Son T. Do; Thuan T. Nguyen; Ruel T. Garcia; Tuan Nguy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB 👁 2 views

Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known. We conducted a mu

Better efficacy of a 12-month interferon

Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter, controlled, randomized trial

✍ Jean-Louis Payen; Jacques Izopet; Virginie Galindo-Migeot; Valérie Lauwers-Cance 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 2 views

We studied the efficacy of three interferon alfa-2b (IFN-2b) regimens for the retreatment of patients with chronic hepatitis C (CHC) with prior complete response followed by relapse. Consecutive patients with CHC who had a complete biochemical response but relapse after a first course of 6 months of

Interferon-α2bInduction Treatment with o

Interferon-α2bInduction Treatment with or Without Ribavirin in Chronic Hepatitis C: A Multicenter, Randomized, Controlled Trial

✍ Hakan Senturk; Galip Ersoz; Resat Ozaras; Sabahattin Kaymakoglu; Hakan Bozkaya; 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 389 KB